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Objective: To investigate the role of junctional adhesion
molecule-A (JAM-A) in the pathogenesis of systemic
sclerosis (SSc).
Methods: Biopsy specimens from proximal and distal
arm skin and serum were obtained from patients with SSc
and normal volunteers. To determine the expression of
JAM-A on SSc dermal fibroblasts and in SSc skin, cell
surface ELISAs and immunohistology were performed. An
ELISA was designed to determine the amount of soluble
JAM-A (sJAM-A) in serum. Myeloid U937 cell–SSc
dermal fibroblast and skin adhesion assays were
performed to determine the role of JAM-A in myeloid cell
adhesion.
Results: The stratum granulosum and dermal endothelial
cells (ECs) from distal arm SSc skin exhibited significantly
decreased expression of JAM-A in comparison with
normal volunteers. However, sJAM-A was increased in
the serum of patients with SSc compared with normal
volunteers. Conversely, JAM-A was increased on the
surface of SSc compared with normal dermal fibroblasts.
JAM-A accounted for a significant portion of U937 binding
to SSc dermal fibroblasts. In addition, JAM-A contributed
to U937 adhesion to both distal and proximal SSc skin.
Conclusions: JAM-A expression is dysregulated in SSc
skin. Decreased expression of JAM-A on SSc ECs may
result in a reduced response to proangiogenic basic
fibroblast growth factor. Increased JAM-A expression on
SSc fibroblasts may serve to retain myeloid cells, which in
turn secrete angiogenic factors.
The pathogenesis of systemic sclerosis (SSc) is
complex and remains incompletely understood;
however, fibroblasts, monocytes and endothelial
cells (ECs) seem to be key players. These cells
facilitate excessive synthesis of extracellular matrix
proteins and deposition of increased amounts of
collagen, immune activation and vascular damage,
all of which are known to be important in the
development of this illness.1
Adhesion molecules have multiple roles in
angiogenesis. Specific adhesion molecule expres-
sion can mediate angiogenesis indirectly by
promoting the migration of monocytes.2 These
monocytes are then capable of becoming tissue
macrophages and secreting angiogenic factors.
Cellular adhesion molecules may have a role in
the immunopathogenesis of SSc.3 We and others
have shown that several adhesion molecules are
overexpressed in SSc skin.4 5 A number of
soluble adhesion molecules are also elevated in
SSc.3
Junctional adhesion molecule-A (JAM-A) has
been implicated in a variety of physiological and
pathological processes involving cellular adhesion,
tight junction assembly and leukocyte transmigra-
tion.6 7 It facilitates leukocyte adhesion and trans-
migration through its interaction with lymphocyte
function-associated antigen-1 (LFA-1). JAM-A has
been shown to play a part in angiogenesis.8
As SSc is characterised by both inflammatory
cell infiltration and vasculopathy, we hypothesised
that JAM-A may have a role in its pathogenesis.
Here we demonstrate aberrant expression of
JAM-A in SSc skin and soluble JAM-A (sJAM-A) in
SSc serum. Moreover, we show a novel role for JAM-A
in mediating myeloid cell adhesion to SSc skin.
MATERIALS AND METHODS
Patients and controls
Skin punch biopsy specimens and peripheral blood
samples were obtained from subjects with SSc (all
with diffuse disease) and control subjects. All
patients with SSc fulfilled the American College
of Rheumatology criteria for SSc and also met the
criteria for diffuse SSc.1 9 Biopsy specimens were
taken with full informed consent and this study
was approved by the institutional review board.
Immunohistology
We performed immunohistological staining on
cryosections from SSc and normal skin, as
described previously.10 Goat anti-human JAM-A
antibody (R&D Systems, Minneapolis, Minnesota,
USA) was used as a primary antibody. The slides
were read by a pathologist under blinded condi-
tions. For JAM-A staining, the percentage of
positive cells was calculated semiquantitatively as
stained cells in proportion to all cells of a
distinctive subset. We also used a similar method
with an anti-von Willebrand factor antibody to
identify endothelial cells. Blood vessels were scored
using a scale of 0–4: 0, avascular; 1, slight decrease;
2, normal; 3, slight increase; 4, marked increase.
Immunofluorescence
We performed immunofluorescence on cryosec-
tions from SSc and normal skin. Sections were
fixed with 4% formalin and blocked with 20% fetal
bovine serum and 5% donkey serum. Goat anti-
human JAM-A antibody (R&D Systems) and
mouse anti-human von Willebrand factor (Dako,
Denmark) were used as primary antibodies.
Fluorescent conjugated secondary antibodies were
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purchased from Molecular Probes (Eugene, Oregon, USA). 49,6-
Diamidino-2-phenylindole was used to stain cell nuclei. Images
were taken at 4006.
Cell lysis and western blotting
Normal and SSc dermal fibroblast cell lines were established as
described previously.11 Cell lysis and western blotting were
performed as described.10 Membranes were probed with anti-
human JAM-A antibody (R&D Systems). Densitometric analy-
sis of the bands was performed using UN-SCAN-IT software,
version 5.1 (Silk Scientific).
Cell surface ELISA
Cell surface ELISAs were performed as previously described.10
Dermal fibroblasts were plated in 96-well plates, stimulated
with tumour necrosis factor a (TNFa), or interleukin 1b (IL1b),
or interferon c (all 25 ng/ml, R&D Systems) or incubated in
serum-free RPMI for 24 h. The fibroblasts were incubated with
anti-human JAM-A antibody (R&D Systems) or goat IgG.
Human dermal microvascular endothelial cell (HMVEC) cell
culture
HMVECs were obtained from Lonza (Basel, Switzerland) and
cultured using EBM complete media (Lonza). The cells were
serum starved overnight and then stimulated with either TNFa
or IL1b. Supernatants were collected and concentrated using
Amicon ultra filters (Millipore, Billerica, Massachusetts, USA).
Serum JAM-A ELISA
Ninety-six-well microplates were coated with anti-human
JAM-A antibody (R&D Systems) and blocked with 1% bovine
serum albumin in phosphate-buffered saline. A sample or
standard (R&D Systems) was added, followed by the addition
of mouse anti-human JAM-A antibody (Santa Cruz, Santa
Cruz, California, USA), anti-mouse biotinylated antibody
(Vector Laboratories, Burlingame, California, USA), streptavi-
din-horseradish peroxidase (R&D Systems), tetramethylbenzi-
dine substrate solution and 2N H2SO4. The absorbance of each
well was read using a microplate reader at 450/570 nm. The
diction limit of the sJAM-A ELISA was 0.3 ng/ml.
U937 cell–fibroblast adhesion assay
Adhesion assays were performed as previously described using
myeloid U937 cells.10 These cells are human histiocytic
lymphoma cells that are myeloid. Combinations of JAM-A
neutralising antibody (Santa Cruz), mouse antibody to human
CD11a (GeneTex, Irvine, California, USA), neutralising mouse
anti-human intercellular adhesion molecule-1 (ICAM-1) anti-
body (R&D Systems), or mouse IgG were used. The inhibitory
effect of neutralising antibody treatment was given as the
percentage of maximal binding, which was defined as the
number of adherent cells in the control antibody-treated
sections.
Stamper–Woodruff adhesion assay
In situ assays were performed as previously described.10 JAM-A
neutralising antibody (R&D Systems) or goat IgG control was
added to the skin sections.U937 cells were labelled with Calcein-
AM fluorescent dye (5 mM, Invitrogen, Carlsbad, California,
USA), added to the sections and incubated for 1 h in the dark.
Non-adherent cells were washed off. The total number of
fluorescence-labelled U937 cells was counted by a blinded
observer using a fluorescence microscope. The inhibitory effect
of the anti-JAM-A antibody was given as the percentage of
maximal binding, which was defined as the number of adherent
cells in the control antibody-treated sections.
Statistical analysis
Student t tests were performed and p values ,0.05 were




The SSc group comprsied 18 women and two men (52.5 (1.8)
years), while the normal control group consisted of seven men
and three women (51.2 (4.4) years). The mean disease duration
of the SSc group was 3.7 (0.8) years. Punch biopsy specimens
were taken from clinically less affected proximal arm skin
(mean skin score 1.2 (0.2)) and affected distal forearm skin (2.0
(0.2)). The proximal biopsy site was far away from the leading
edge of the distal area.
SSc distal arm skin had significantly fewer blood vessels than
normal skin
Our work confirmed that in our patient population SSc distal
arm skin has significantly fewer blood vessels (blood vessel
score = 1.7) than normal skin (blood vessel score = 2.0, p,0.05)
(fig 1).12 In addition, we found that SSc proximal arm skin
(blood vessel scale score = 1.9) had a blood vessel score between
that of SSc distal skin and normal skin.
JAM-A is abnormally expressed in SSc skin
JAM-A expression in normal and SSc skin was evaluated using
immunohistology and immunofluorescence. JAM-A is
expressed on dermal ECs, fibroblasts, macrophages and in
the epidermis (fig 2). Moreover, dual immunofluorescence
using anti-JAM-A and anti-von Willebrand factor antibodies
further indicated that JAM-A is expressed on dermal ECs. As
shown in fig 2I, quantification of JAM-A immunohistology
demonstrated that SSc dermal ECs exhibited significantly
decreased expression of JAM-A (mean of 71%) compared with
normal controls (mean of 93%, p,0.05). In addition, JAM-A
was less expressed in the stratum granulosum of the epidermis
of distal SSc skin (mean of 50%) than in normal skin (mean of
98%, p,0.05, fig 2J). In contrast, SSc dermal perivascular
macrophages expressed increased levels of JAM-A (12% in
distal skin and 18% in proximal skin) compared with normal
Figure 1 Distal systemic sclerosis (SSc) skin has fewer blood vessels
than normal skin. n = the number of patients.
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skin (mean of 4%, both p,0.05) (data not shown). Similarly,
SSc subepidermal macrophages expressed increased levels of
JAM-A (mean of 8% in distal skin and mean of 8% in proximal
skin) compared with normal skin (mean of 3%, both p,0.05)
(data not shown).
JAM-A was more highly expressed on dermal SSc fibroblasts
than on normal dermal fibroblasts
JAM-A was more highly expressed on dermal SSc fibroblasts
than on normal fibroblasts (fig 3A). Western blotting resulted in
similar results (fig 3B). However, the expression of JAM-A on
either SSc or normal dermal fibroblasts was not inducible by
TNFa, interferon c, or IL1b (data not shown).
Elevated sJAM-A in SSc serum
A sJAM-A ELISA was designed and serum JAM-A was detected
in all normal volunteers and patients with SSc. The concentra-
tion of sJAM-A in the serum of patients with SSc was 2.4
(0.4) ng/ml, whereas the concentration for normal controls was
1.0 (0.2) ng/ml (p,0.05) (fig 4A).
sJAM-A is secreted by ECs
sJAM-A was detectable in the culture supernatant of HMVECs
(fig 4B). Moreover, stimulation with TNFa resulted in a
significant increase of sJAM-A in HMVEC culture supernatants
(p,0.05).
JAM-A mediates myeloid U937 cell binding to SSc dermal
fibroblasts
We found that SSc dermal fibroblasts bound a greater number
of myeloid U937 cells than normal dermal fibroblasts (p,0.05)
(data not shown). Moreover, JAM-A accounted for a significant
portion of U937 binding to SSc dermal fibroblasts. U937 binding
to SSc dermal fibroblasts was inhibited by neutralising anti-
JAM-A antibody treatment (86% of maximal binding, p,0.05)
(fig 5). Neutralising antibody against the JAM-A ligand LFA-1
also inhibited U937 cell binding to SSc dermal fibroblasts (90%
of maximal binding, p,0.05). Similarly, neutralising antibody
against the LFA-1 receptor ICAM-1 inhibited U937 cell binding
to SSc dermal fibroblasts (83% of maximal binding). A
combination of neutralising antibodies against JAM-A, LFA-1
Figure 2 Immunohistological and immunofluorescence analysis of junctional adhesion molecule-A (JAM-A) on normal and systemic sclerosis (SSc)
skin. Representative photos of JAM-A immunohistological staining in endothelial cells of normal skin (A), proximal SSc skin (B), distal SSc skin (C) and
of the isotype control (D) are shown, all at 6200. Arrows indicate positive JAM-A staining of vasculature. Representative photos of dual
immunofluorescence staining of JAM-A and von Willebrand factor (vWF) in normal skin (E), proximal SSc skin (F), distal SSc skin (G) and of the isotype
control (H) are shown, all at 6400. Arrows indicate dermal blood vessels. (I) Dermal endothelial cells from proximal and distal SSc skin exhibited
decreased expression of JAM-A compared with normal skin. (J) JAM-A was less expressed in the stratum granulosum of SSc skin than in normal skin.
n = the number of patients.
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and ICAM-1 resulted in the greatest inhibition of U937 cell
binding to SSc dermal fibroblasts (73% of maximal binding).
JAM-A contributes to U937 cell adhesion to SSc skin
We found that similar to the results of the U937-fibroblast in
vitro adhesion assay, anti-JAM-A neutralising antibody
decreased U937 cell binding to SSc skin (fig 6). U937 cell
binding to SSc proximal arm skin (44% of maximal binding,
p,0.05) and distal forearm skin (61% of maximal binding,
p,0.05) was inhibited by anti-JAM-A antibody treatment.
Collectively, these results indicate that JAM-A plays an
important role in myeloid cell adhesion to SSc skin.
DISCUSSION
The aetiology and pathogenesis of SSc remains unknown.
Nonetheless, signs of vascular injury and devascularisation of
affected organs in association with evidence of profound
endothelial dysfunction are well documented. Adhesion mole-
cules, molecules known to promote both inflammatory cell
infiltration and angiogenesis, may have a role in the pathogen-
esis of SSc.3
Our results demonstrated that dermal ECs from SSc skin
exhibit decreased expression of JAM-A compared with ECs in
normal skin. Decreased JAM-A expression increases permeabil-
ity. Blocking JAM-A expression caused a decrease in neutrophil
and monocyte extravasation in several models, including
inflammatory meningitis, peritonitis and ischaemia-reperfusion
injury.13–16 These findings suggest that the downregulation of
JAM-A expression on SSc dermal ECs may effect the influx of
leukocytes into SSc skin.
In addition, JAM-A is a proangiogenic adhesion molecule. It
forms a complex with integrin avb3 and mediates basic
fibroblast growth factor (bFGF)-induced angiogenesis.8 JAM-A
overexpression on ECs induces both EC proliferation and
migration on vitronectin. In addition, inhibition of JAM-A
signalling blocks bFGF-induced EC proliferation, tube formation
and in vivo angiogenesis.8 17 Our results demonstrate that
JAM-A is downregulated on SSc dermal ECs and therefore
may not be able to respond to bFGF and mediate angiogenesis.
Soluble adhesion molecules have also been shown to be
elevated in patients with SSc. Recently, Cavusoglu et al
observed significantly higher levels of plasma sJAM-A in
patients with advanced coronary artery disease and indicated
that JAM-A may be an important mediator of the effects of
inflammation on the vessel wall.18 Our results show that the
concentration of sJAM-A in the serum of patients with SSc is
elevated compared with normal serum. Moreover, we demon-
strated that sJAM-A can be secreted by cultured ECs. This is the
first study to suggest a link between serum sJAM-A concentra-
tion and SSc and further study is needed to determine if the
Figure 3 Junctional adhesion molecule-A (JAM-A) is overexpressed on systemic sclerosis (SSc) dermal fibroblasts than on normal (NL) dermal
fibroblasts (A). A representative western blot is shown in (B); expression of JAM-A protein is higher in SSc dermal fibroblasts. n = the number of
different SSc patient or normal volunteer derived fibroblast cell lines.
Figure 4 Soluble junctional adhesion molecule-A (sJAM-A) is elevated in the serum of patients with systemic sclerosis (SSc) and secreted by human
dermal microvascular endothelial cells (HMVECs). The concentration of sJAM-A in SSc serum was significantly greater than in normal control serum
(A). n, the number of patients. sJAM-A is found in the culture supernatants of HMVECs (B) and its expression is increased with stimulation by tumour
necrosis factor a (TNFa). IL1b, interleukin 1b; n = the number of replicates.
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Figure 5 Junctional adhesion molecule-A (JAM-A) mediates adhesion of U937 cells to systemic sclerosis (SSc) dermal fibroblasts. U937 binding to
SSc dermal fibroblasts was inhibited by anti-JAM-A antibody and anti-LFA-1 antibody (A). U937 cell binding to SSc dermal fibroblasts was inhibited by
anti-ICAM-1 antibody and a combination of anti-ICAM-1, LFA-1 and JAM-A antibodies (B). LFA-1, lymphocyte function-associated antigen-1 ; ICAM-1,
intercellular adhesion molecule-1; n = the number of different fibroblast cell lines from patients with SSc.
Figure 6 Junctional adhesion molecule-A (JAM-A) mediates adhesion of U937 cells to systemic sclerosis (SSc) skin. (A) U937 binding to SSc
proximal arm skin and distal arm skin sections was inhibited by anti-JAM-A antibody treatment. Representative photos of the effect of anti-JAM-A on
U937 cell adhesion to distal SSc skin (B), proximal SSc skin (C) and in the presence of an IgG control in place of anti-JAM-A (D) are shown, all at6100.
n = the number of patients.
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concentration of serum sJAM-A correlates with additional
clinical manifestations of SSc.
Previous studies have shown that SSc peripheral blood mono-
nuclear cells and SSc dermal fibroblasts are hyperadhesive.19 Here
we found that JAM-A is overexpressed on SSc dermal fibroblasts
and mediates the adhesion of myeloid U937 cells to both SSc
dermal fibroblasts and proximal and distal SSc skin. As myeloid
cells mature into monocytes and macrophages that have the
potential to secrete a variety of angiogenic factors, our results have
particular importance to the pathogenesis of SSc.
Our study suggests that JAM-A plays multiple roles in the
pathogenesis of SSc. The reduced expression of JAM-A on the
surface of ECs may contribute to dysregulated angiogenesis in
SSc skin, as JAM-A EC expression is required for bFGF-induced
angiogenesis.8 20 21 Moreover, the elevated SSc serum levels of
sJAM-A could be the result of the characteristic EC injury in
SSc, further strengthening the suggestion of JAM-A as a
vascular disease marker.18 In contrast, JAM-A exemplifies the
dual nature of an adhesion molecule, as our results demonstrate
its importance in mediating myeloid cell retention in SSc skin.
Collectively, these results suggest that JAM-A is dysregulated
on multiple cell types in SSc and that further study of its role in
SSc skin angiogenesis is warranted.
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